ZNF890P: A Potential Drug Target and Biomarker (G645700)

Target Name: ZNF890P

NCBI ID: G645700

ZNF890P

Other Name(s): zinc finger protein 890, pseudogene | Zinc finger protein 890, pseudogene

ZNF890P: A Potential Drug Target and Biomarker

Zinc finger proteins (ZFPs) are a family of transmembrane proteins that play a crucial role in various cellular processes. ZNF890P, also known as zinc finger protein 890, is a ZFP that has been identified as a potential drug target and biomarker. In this article, we will discuss the ZNF890P protein, its functions, potential drug targets, and its potential as a biomarker for various diseases.

Description of ZNF890P

ZNF890P is a 21-kDa protein that consists of 216 amino acid residues. It has a characteristic ZNF-like domain, which is responsible for its unique structure and function. The ZNF-like domain is composed of a nucleotide-binding oligomerization (NBO) domain and a C-terminal domain that contains a conserved core sequence responsible for ZNF-like interactions.

Expression and Localization

ZNF890P is expressed in various tissues and organs, including brain, heart, liver, and pancreas. It is primarily localized to the cytoplasm and is also detected in the endoplasmic reticulum (ER) and the nuclear envelope (NE). ZNF890P is a protein that is involved in various cellular processes, including cell signaling, cell adhesion, and cell survival.

Potential Drug Target

ZNF890P has been identified as a potential drug target due to its unique structure and function. It has been shown to play a role in various signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and survival. ZNF890P has been shown to interact with the transcription factor Smad2 and has been shown to regulate the expression of target genes that are involved in cell growth, differentiation, and survival.

In addition to its role in the TGF-β pathway, ZNF890P has also been shown to play a role in the Wnt signaling pathway. Wnt signaling is involved in cell-to-cell and cell-to-environmental signaling and is critical for various cellular processes, including cell growth, differentiation, and survival. ZNF890P has been shown to interact with the protein 尾-catenin, which is a key component of the Wnt signaling pathway.

Potential Biomarker

ZNF890P has been shown to have potential as a biomarker for various diseases. For example, it has been shown to be involved in the development and progression of cancer, including breast cancer. ZNF890P has been shown to promote the growth and survival of cancer cells and has been shown to play a role in the development of resistance to chemotherapy in cancer cells.

In addition to its role in cancer, ZNF890P has also been shown to be involved in the development and progression of other diseases, including neurodegenerative diseases. ZNF890P has been shown to promote the neurotoxicity of various neurotoxins, including the neurotoxin BMAA, which is involved in the development of neurodegenerative diseases.

Conclusion

In conclusion, ZNF890P is a unique and highly expressed protein that has been shown to play a role in various cellular processes. Its potential as a drug target and biomarker makes it an attractive target for further research. Further studies are needed to fully understand the functions of ZNF890P and its potential as a drug and biomarker.

Protein Name: Zinc Finger Protein 890, Pseudogene

The "ZNF890P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF890P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets